Care pathways & referral

Cardiac rehab saves lives. Health systems still treat it like optional aftercare

England Moved the Vaccine Clock. The Coverage Gap Stayed Put

Resistant hypertension may need a diagnostic revolution, not just another drug

When diabetes tech fails, personalised care fails with it

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

MS Does Not End at the Clinic Door. It Follows People Into Work, Money and Relationships.

For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door

Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
